新药Rilzabrutinib在治疗免疫性血清细胞露天病方面显示出巨大的好处,增加了患者的希望。 New drug Rilzabrutinib shows significant benefits in treating immune thrombocytopenia, raising hopes for patients.

Rilzabrutinib是一种新的口服药物,它给免疫性血清细胞硬化(ITP)病人带来很大好处,这种疾病导致小盘数低。 Rilzabrutinib, a new oral medication, has shown significant benefits for patients with immune thrombocytopenia (ITP), a condition causing low platelet counts. 在第三阶段的研究中,它提高了小盘的含量,减少了出血,并提高了生活质量,23%的病人得到持久的反应,而安慰剂上没有。 In a phase 3 study, it improved platelet levels, reduced bleeding, and enhanced quality of life, with 23% of patients achieving a durable response compared to none on the placebo. 美国和欧盟监管机构正在对这一药物进行审查。 The drug is under review by U.S. and EU regulators.